Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | HTT | P42858 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.86 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.74 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22678672 | 1.00 | LMNA (1.00) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL17457017 | 0.83 | LMNA (1.00) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL29306048 | 0.78 | PKM (1.00) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL2628832 | 0.74 | GPR55 (0.75) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL6030972 | 0.71 | ATM (0.62) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL6667999 | 0.70 | PKM (0.63) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6761545 | 0.69 | PKM (0.61) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL1793790 | 0.69 | LMNA (0.73) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL6760863 | 0.69 | SMN1; SMN2 (0.63) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL2628836 | 0.68 | SLC2A1 (0.77) | LMNAHTTSMN1; SMN2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | PROMETHEUS BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250041672-A1 | GOLF BALL | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2025-02-06 | — | — | US | disclosed |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-115293511-A | Method and device for regulating and controlling storage capacity of valley section and light air storage system | 珠海格力电器股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3969621-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | Prometheus Biosciences, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | LMNA 1079/4885HTT 1181/4885SMN1; SMN2 238/4885 |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | LMNA 1079/4885HTT 1181/4885SMN1; SMN2 238/4885 |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | TLL1, TSG101, DNASE1L3 | LMNA 1895/4885HTT 2585/4885SMN1; SMN2 2649/4885 |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | DNASE1L3, TLL1, RNASE1 | LMNA 497/4885HTT 1594/4885SMN1; SMN2 1257/4885 |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | TLL1, TSG101, DNASE1L3 | LMNA 1895/4885HTT 2585/4885SMN1; SMN2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.